XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues:        
Revenues $ 16,000 $ 0 $ 389,000 $ 0
Operating expenses:        
Research and development 5,236,000 4,413,000 15,637,000 13,572,000
General and administrative 1,625,000 2,054,000 4,845,000 5,239,000
Total operating expenses 6,861,000 6,467,000 20,482,000 18,811,000
Operating loss (6,845,000) (6,467,000) (20,093,000) (18,811,000)
Other income (expense):        
Foreign exchange gains (losses) 104,000 276,000 (58,000) 514,000
Interest income 50,000 67,000 243,000 88,000
Other income (expense), net (9,000) 14,000 50,000 1,294,000
Total other income (expense), net 145,000 357,000 235,000 1,896,000
Loss before taxes (6,700,000) (6,110,000) (19,858,000) (16,915,000)
Income tax benefit 668,000 1,014,000 2,574,000 3,136,000
Net loss (6,032,000) (5,096,000) (17,284,000) (13,779,000)
Dividend on convertible exchangeable preferred shares (50,000) (50,000) (151,000) (151,000)
Net loss applicable to common shareholders $ (6,082,000) $ (5,146,000) $ (17,435,000) $ (13,930,000)
Redeemable common shareholders        
Basic and diluted earnings per common share:        
Net loss per share - basic $ (0.48) $ (0.38) $ (1.39) $ (1.10)
Net loss per share - diluted $ (0.48) $ (0.38) $ (1.39) $ (1.10)
Weighted average common shares outstanding basic 740,379 2,376,721 2,307,279 809,821
Weighted average common shares outstanding diluted 740,379 10,013,317 2,307,279 809,821
Common Stock        
Basic and diluted earnings per common share:        
Net loss per share - basic $ (0.48) $ (0.43) $ (1.39) $ (1.30)
Net loss per share - diluted $ (0.48) $ (0.43) $ (1.39) $ (1.30)
Weighted average common shares outstanding basic 11,902,443 9,937,958 10,271,036 10,013,317
Weighted average common shares outstanding diluted 11,902,443 9,937,958 10,271,036 2,376,721
Clinical trial supply        
Revenues:        
Revenues $ 16,000   $ 389,000